We assessed the effects of angiotensin-converting enzyme (ACE) inhibition on survival and
cardiorenal outcomes in a consecutive cohort of Chinese type 2 diabetic patients with …

Background There is much uncertainty regarding the relative effects of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in …

Diabetic nephropathy, the most common cause of end-stage renal disease in the United
States, is also associated with increased cardiovascular mortality. The renin-angiotensin …

BACKGROUND: Cardiovascular disease is the leading cause of mortality in patients with
kidney failure treated with hemodialysis (HD). Although angiotensin receptor blockers …

The aim of this study was to assess the effects of angiotensin receptor blocker (ARB)-based
therapy on cardiovascular events in high-risk hypertensive patients with coronary artery …

There is a rising incidence and prevalence of ESRD as a result of diabetes, with poor
outcome and growing costs. Recently, two large trials, the Irbesartan Diabetic Nephropathy …

Background: Patients with diabetes have increased risk for adverse cardiovascular events.
Angiotensin-converting enzyme inhibitors are protective in type 1 diabetes. However, no …

Purpose Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker
(ARB) are associated with a decreased incidence of new-onset diabetes mellitus (NODM) …

Abstract Background and Aims Although many angiotensin receptor blockers (ARBs) are
widely used, comparative data regarding their impact on clinical outcomes are limited. We …

Blockade of the effects of angiotensin II (Ang II) by using an angiotensin-converting enzyme
(ACE) inhibitor has been proven to be of value in Type 1 diabetic nephropathy and in non …